Natera (NTRA) Company Report

Natera presented new data on its Signatera MRD test at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), highlighting its potential utility across genitourinary cancers, including for bladder preservation.
Data from the INDIBLADE and RETAIN trials demonstrated that Signatera-negativity post-therapy was strongly associated with positive outcomes, such as improved bladder-intact event-free survival and metastasis-free survival in muscle-invasive bladder cancer.
The NIAGARA study included the first-ever presentation of urinary tumor DNA (utDNA) data with clinical correlation, suggesting that the combined assessment of utDNA and circulating tumor DNA (ctDNA) can provide comprehensive risk stratification for residual disease.

11 hours ago

Press Release

Natera Reports Strong Q4 2025 Results and Provides 2026 Guidance

NTRA

Earnings

Guidance Update

Product Launch

Natera reported Q4 2025 revenue of $666 million, a 40% increase over Q4 2024, and achieved a gross margin of 66.9%. The company generated over $107 million in cash flow for the full year 2025.
For 2026, Natera initiated guidance expecting revenues between $2.62 billion-$2.7 billion and gross margins between 63%-65%. This revenue guidance implies approximately 25% growth over 2025, excluding true-ups.
Key product developments include the launch of the Latitude tissue-free MRD test and the 21 gene Fetal Focus single gene NIPT test. The company also integrated phased variant technology from the Foresight Diagnostics acquisition, enhancing Signatera's ultra-sensitivity.
Natera plans to hold SG&A stable while making targeted investments in R&D and pursuing broader Medicare reimbursement for Signatera to drive future margin expansion.

1 day ago

Transcript

Natera Reports Strong Q4 2025 Results and Provides 2026 Guidance

NTRA

Earnings

Guidance Update

Product Launch

Natera reported Q4 2025 revenue of ~$666 million, representing ~40% year-over-year growth compared to Q4 2024, with ~924K total tests processed and ~225K clinical MRD tests.
The company achieved a gross margin of ~66.9% in Q4 2025, an increase from 62.9% in Q4 2024, and generated ~$107.6 million in cash inflow for the full year 2025.
For 2026, Natera is establishing a financial outlook with projected revenue between $2.62 billion and $2.70 billion, a gross margin of 63%-65%, and anticipates positive cash inflow.
Key business highlights in 2025 included the launch of Fetal Focus Single-Gene NIPT and Latitude Tissue-Free MRD, along with Medicare coverage for Signatera in Lung Cancer Surveillance and Signatera Genome.

1 day ago

Presentation

Natera Announces Strong Q4 2025 Results and Provides 2026 Guidance

NTRA

Earnings

Guidance Update

Product Launch

Natera reported strong Q4 2025 financial results, with $666 million in revenue, representing approximately 40% revenue growth over Q4 2024, and a gross margin of 66.9%. The company also generated over $107 million in cash flow in 2025.
The company processed approximately 924,000 tests in Q4 2025, with MRD clinical units growing by 56% compared to Q4 2024, reaching 225,000 tests processed.
For 2026, Natera initiated guidance projecting revenues between $2.62 billion and $2.7 billion and gross margins between 63% and 65%, expecting another strong cash flow year.
Significant product developments include the launch of the Latitude tissue-free MRD test and the 21 gene Fetal Focus single gene NIPT test, alongside the integration of phased variant technology into Signatera following the Foresight Diagnostics acquisition.

1 day ago

Transcript

Natera Reports Strong Q4 2025 Results and Provides 2026 Guidance

NTRA

Earnings

Guidance Update

Product Launch

Natera reported Q4 2025 revenue of $666 million, representing 40% year-over-year growth, and achieved a record gross margin of 66.9%. The company generated over $107 million in cash flow for 2025.
For 2026, Natera projects revenues between $2.62 billion and $2.7 billion and gross margins of 63% to 65%. Operating expenses are expected to grow approximately 9.5% at the midpoints.
Key product advancements include the launch of the 21-gene Fetal Focus single gene NIPT test and the submission of the Latitude tissue-free MRD assay to MolDX. The company also integrated phased variants technology from the Foresight Diagnostics acquisition into its Signatera platform, with a clinical launch planned for this year.
Natera is actively seeking broader Medicare reimbursement for Signatera, which could provide significant upside beyond the current 2026 guidance.

1 day ago

Transcript

Natera Reports Strong Q4 and Full Year 2025 Financial Results and Provides 2026 Outlook

NTRA

Earnings

Guidance Update

Revenue Acceleration/Inflection

Natera reported strong financial results for Q4 2025, with total revenues of $665.5 million, a 39.8% increase year-over-year, and full-year 2025 total revenues of $2,306.1 million, up 35.9% from 2024.
The company processed approximately 923,600 tests in Q4 2025 and 3,525,500 tests in full-year 2025, reflecting increases of 16.5% and 15.0% respectively, driven by significant growth in oncology tests.
Natera's gross margin improved to 66.9% in Q4 2025 and 64.7% for the full year 2025, compared to 62.9% and 60.3% in the prior year periods.
For the full year 2025, the company reported a net loss of $208.2 million, or ($1.52) per diluted share, and achieved positive cash inflow of approximately $107.6 million.
Looking ahead, Natera anticipates 2026 total revenue between $2.62 billion and $2.70 billion, a gross margin of approximately 63% to 65%, and expects to maintain positive net cash inflow.

1 day ago

8-K

Natera Reports Strong Q4 and Full Year 2025 Financial Results with Positive 2026 Outlook

NTRA

Earnings

Revenue Acceleration/Inflection

Guidance Update

Natera reported total revenues of $2,306.1 million for the full year 2025, an increase of 35.9% compared to the full year 2024, and $665.5 million for the fourth quarter of 2025, up 39.8% from the prior year period.
The company achieved a gross margin of 64.7% for the full year 2025 and 66.9% for the fourth quarter of 2025, both improvements over the previous year.
Test volumes saw substantial growth, with 3,525,500 tests processed in full year 2025 (+15.0%) and 923,600 tests processed in Q4 2025 (+16.5%), including a significant increase in oncology tests.
Natera generated positive cash inflow of approximately $107.6 million for the full year 2025.
For 2026, Natera anticipates total revenue between $2.62 billion and $2.70 billion and a gross margin of approximately 63% to 65%.

1 day ago

Press Release

Natera Announces Positive Phase 2 SINERGY Trial Results for Signatera in Head and Neck Cancer

NTRA

Product Launch

New Projects/Investments

Natera announced successful results from its Phase 2 SINERGY trial for Signatera™ in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
The trial achieved a strong 63% objective response rate (ORR), which compares favorably to historical controls.
Signatera-guided treatment reduced chemotherapy exposure for 74% of patients, resulting in a median of 2 chemotherapy cycles, a two-thirds reduction from the current standard of care.
The study also reported substantially lower severe toxicity (48.1%) compared to historical controls.

4 days ago

Press Release

Natera Submits Signatera CDx PMA to FDA

NTRA

Natera has submitted its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for Signatera™ CDx.
The submission is for the detection of molecular residual disease (MRD) in patients with muscle-invasive bladder cancer (MIBC) who may benefit from treatment with atezolizumab (Tecentriq®).
This application is supported by data from the randomized, double-blind, phase 3 IMvigor011 clinical trial, which met its primary endpoint and demonstrated significant improvements in disease-free survival and overall survival for Signatera-positive patients treated with atezolizumab.
If approved, Signatera CDx has the potential to be the first companion diagnostic MRD test to guide treatment decisions and improve outcomes for MIBC patients.

Feb 2, 2026, 11:00 AM

Press Release

Natera Completes Enrollment in Pivotal Heart Transplant Trial

NTRA

New Projects/Investments

Product Launch

Natera, Inc. (NTRA) has completed enrollment in its ACES-EMB trial, a randomized-controlled study evaluating the Prospera Heart test for rejection monitoring in heart transplant recipients.
This trial is the first randomized-controlled study to compare non-invasive donor-derived cell-free DNA (dd-cfDNA) surveillance with routine invasive biopsies in organ transplantation.
Positive results could lead to a fundamental shift in the standard of care, replacing invasive biopsies with the non-invasive Prospera test for approximately 4,500 heart transplants annually in the United States.

Jan 28, 2026, 1:00 PM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for Natera.

Q4 2025

Feb 26, 2026

→

Q3 2025

Nov 6, 2025

→

Q2 2025

Aug 7, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Steven Chapman say about margins?What are Natera's strategic priorities?How is Natera positioned vs competitors?How did Natera do last quarter?

Natera (NTRA)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Steven Chapman

Daniel Rabinowitz

John Fesko

Matthew Rabinowitz

Michael Brophy

Solomon Moshkevich

Board Members

Gail Marcus

Herm Rosenman

Jonathan Sheena

Monica Bertagnolli

Roelof Botha

Rowan Chapman

Roy Baynes

Ruth Williams-Brinkley

Analyst Coverage

Puneet Souda

Catherine Schulte

Daniel Brennan

Doug Schenkel

Tycho Peterson

Casey Woodring

Rachel Vatnsdal Olson

Tejas Savant

Dan Brennan

Dan Leonard

David Westenberg

Douglas Schenkel

Ricki Levitus

Colleen Babington

Daniel Leonard

Daniel Markowitz

Matthew Sykes

Matt Sykes

Noah

Rachel Vatnsdal

Subbu Nambi

Subhalaxmi Nambi

Latest news

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent